Advertisement
Advertisement

Tell Johnson & Johnson to Stop Turning Its Back on AIDS Patients

J&J Is Undermining Access to Key AIDS Drugs

December 15, 2011

Tell Johnson & Johnson to Stop Turning Its Back on AIDS Patients

On Monday, December 19, pharmaceutical giant Johnson & Johnson is expected to announce whether it intends to license its patents on three lifesaving HIV/AIDS drugs to the Medicines Patent Pool, a mechanism designed to lower prices of HIV medicines and increase access to them for people in the developing world.

The time to act is now!

Tell J&J to join the patent pool

Over the past two years, Doctors Without Borders/Médecins Sans Frontières (MSF) has been urging Johnson & Johnson to take this critical step.

Johnson & Johnson has so far refused to join discussions on licensing these patents to the Medicines Patent Pool. The Pool has been set up to increase access to more affordable versions of HIV drugs, including fixed-dose combinations that include multiple medicines in one pill, and to develop much-needed pediatric HIV drugs.

The Pool would license patents on HIV drugs to other manufacturers and the resulting competition would dramatically reduce prices, making them much more affordable in the developing world. However, since the Pool is voluntary it will only work if patent holders like Johnson & Johnson choose to participate.




This article was provided by Doctors Without Borders.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.